Crinetics Pharmaceuticals, Inc. 4

Caren Deardorf, an insider of Crinetics Pharmaceuticals, Inc., had all of her common shares, RSUs, and in‑the‑money stock options canceled and cashed out at the $85.00 per‑share merger price in connection with Vertex Pharmaceuticals’ acquisition of Crinetics.

On September 1, 2026, in connection with the closing of Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals, Inc., reporting person Caren Deardorf had all of her Crinetics equity canceled and cashed out at the $85.00 per‑share merger price. This included 16,300 shares of common stock and 5,925 restricted stock units that became fully vested immediately prior to the effective time and were then converted into cash at $85 per share, for an estimated $1.88 million in total common/RSU consideration. In addition, multiple tranches of vested stock options with exercise prices below the $85 merger price were canceled and converted into cash equal to the spread between $85 and the exercise price, including 35,000 options at a $19.30 exercise (spread $65.70), 4,375 options at $18.29 (spread $66.71), 17,500 options at $20.32 (spread $64.68), 12,500 options at $44.71 (spread $40.29), 10,350 options at $32.33 (spread $52.67), and 9,730 options at $35.87 (spread $49.13), for an additional estimated cash consideration of roughly $6.3 million. Following the merger-related cancellations, Deardorf reported zero shares and zero options of Crinetics, leaving no continuing equity ownership in the now‑private subsidiary.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059901

Alert Tier

7